Scintigraphic comparison of budesonide deposition from two dry powder inhalers

European Respiratory Journal

Volumn 16, Issue 1, 2000, Pages 178-183

  Newman, S P ^a   Pitcairn, G R ^a   Hirst, P H ^a   Bacon, R E ^a   O'Keefe, E ^b   Reiners, M ^b   Hermann, R ^b  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^b ASTA Medica AG   (United Kingdom)

Author keywords

Budesonide; Dry powder inhaler; Gamma scintigraphy; Total and regional lung deposition

Indexed keywords

BUDESONIDE; CHLOROFLUOROCARBON;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG FORMULATION; DRY POWDER; FEMALE; GAMMA SCINTIGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; INSPIRATORY CAPACITY; ISOTOPE LABELING; MALE; METERED DOSE INHALER; NORMAL HUMAN; PEAK EXPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; POWDERS; TECHNETIUM;

EID: 0033911733     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.16a29.x     Document Type: Article

References (27)

1. 1. Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Technol 1995; 22: 374-391.
2. Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler. Int J Pharm 1994; 102: 127-132.
3. Berner B, Fyrnys B, de Boer A, Göttenhauer W, Wolf-Heuss E. Asta Medica multidose dry powder inhaler. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL, USA, Interpharm Press, 1998; pp. 475-477.
4. Newman SP, Steed KP, Hooper G, Källén A, Borgström L. Comparison of gamma scintigraphy and a pharmaco-kinetic technique for assessing the pulmonary deposition of terbutaline sulphate delivered by pressurised metered dose inhaler. Pharm Res 1995; 12: 231-236.
5. Newman SP. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Syst 1993; 10: 65-109.
6. Newman SP. Scintigraphic assessment of pulmonary delivery systems. Pharm Tech 1998; 22: 78-94.
7. Quanjer PH, Tammeling GH, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Predicted values for spirometric lung function tests. Eur Respir J 1993; 6: Suppl. 16, 5-40.
8. Thorsson L, Newman SP, Weisz A, Trofast E, Moren F. Nasal distribution of budesonide inhaled via a powder inhaler. Rhinology 1993; 31: 7-10.
9. Pitcairn GR, Lunghetti G, Ventura P, Newman SP. A comparison of the lung deposition of salbutamol inhaled from a new dry powder inhaler, at two inhaled flow rates. Int J Pharm 1994; 102: 11-18.
10. Pitcairn GR, Lim J, Hollingworth A, Newman SP. Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. J Aerosol Med 1997; 10: 295-306.
11. Newman SP. Characteristics of radiolabelled versus unlabelled formulations. J Aerosol Med 1996; 9 (Suppl. 1): S37-S47.
12. Pitcairn GR, Newman SP. Tissue attenuation corrections in gamma scintigraphy. J Aerosol Med 1997; 10: 187-198.
13. Newman SP, Clark SR, Talaee N, Clarke SW. Pressurised aerosol deposition in the human lung with and without an "open" spacer. Thorax 1989; 44: 706-710.
14. Partridge MR, Woodcock AA, Sheffer AL, Wanner A, Rubinfeld A. Chlorofluorocarbon-free inhalers: are we ready for the change?. Eur Respir J 1998; 1: 1006-1008.
15. Keeley D, Rees J. New guidelines on asthma management. BMJ 1997; 314: 315-316.
16. British Asthma Guidelines Coordinating Committee. British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: S1-S24.
17. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clin Immunother 1996; 6: 273-299.
18. Pauwels R, Newman SP, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered dose inhalers. Eur Respir J 1997; 10: 2127-2138.
19. Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Respir Med 1999; 93: 123-133.
20. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157: S1-S53.
21. Newman SP, Morén F, Trofast E, Talaee N, Clark SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J 1989; 2: 247-252.
22. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler. Eur Respir J 1994; 7: 1839-1844.
23. Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J 1994; 7: 69-73.
24. Borgström L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effects of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-1640.
25. Melchor R, Biddiscombe MF, Mak VHF, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airways obstruction. Thorax 1993; 48: 506-511.
26. Warren SJ, Taylor G. Effect of inhalation flow profiles on the deposition of radiolabelled BDP from a novel dry powder inhaler (Clickhaler), a conventional metered dose inhaler and MDI plus spacer. In: Dalby RN, Byron PR, Fair SJ, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL, USA, Interpharm Press, 1998; pp. 453-455.
27. Newman SP, Hirst PH, Pitcairn GR, Clark AR. Understanding regional lung deposition in gamma scintigraphy. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory Drug Delivery VI. Buffalo Grove, IL, USA, Interpharm Press, 1998; pp. 9-15.